The race to create a new class of ovarian cancer drugs heats up

(By Meghana Keshavan for STAT)

The race to create the next potent ovarian cancer drug is coming to a head.

Ovarian cancer has historically been one of the harder cancers to treat — but a promising new class of drugs, called PARP inhibitors, is proving powerful in delaying the growth of tumors by preventing cancer cells from repairing themselves after they’ve been damaged by chemotherapy. Continue reading article here……..


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or